What Darnitsa does

Darnitsa (Фармацевтична компанія "Дарниця") is a privately held Ukrainian pharmaceutical manufacturer founded in 1930 and headquartered in Kyiv, employing 501-1,000 people. The company produces over 180 medicinal products organized around three primary therapeutic areas — cardiology, neurology (including PTSD), and pain management — with branded SKUs such as Ibuprofen-Darnitsa, Paracetamol-Darnitsa, Citramon-Darnitsa, Eridez (orodispersible tablets), Darfen Long (extended-release), Darsil (hepatoprotective), and Medikhronal-Darnitsa. Manufacturing is conducted under GMP certification at facilities in Kyiv, which the company also showcases via 3D virtual tours as part of its transparency positioning. The company self-describes as the Ukrainian pharmaceutical market leader by sales volume in natural terms.

Darnitsa operates a multi-channel go-to-market: an own-branded pharmacy at Novodarnytska Street 6 in Kyiv provides direct retail, the Ukrainian government's 'Affordable Medicines' (Доступні ліки) reimbursement program provides subsidized prescription access, the Army+ platform offers a 20% discount channel for military personnel, and export operations distribute products to more than 20 countries internationally. The company also runs an Educational Hub for physicians and patients covering PTSD, pain management, and cardiovascular disease, and co-produces the 'Heart Beats' (Серце б'ється) podcast with the Institute of Heart.

The business model is fundamentally that of a generic and branded-generic pharmaceutical manufacturer: revenue is generated through one-time product sales across retail, government-reimbursed, and export channels, with no disclosed licensing, subscription, or platform-based revenue streams. Pricing is not publicly disclosed but is constrained by participation in the state reimbursement program and by the explicit 20% military discount. Ownership is private and undisclosed, and no funding rounds, M&A activity, or management team details are present in the available data.

Name

Darnitsa

Legal name

Фармацевтична компанія 'Дарниця'

Website

https://darnitsa.ua

Company type

Private

Founded year

1930

Operating status

Operating

Headcount range

251–500 employees

Short description

Darnitsa is a privately held Ukrainian pharmaceutical manufacturer founded in 1930, producing 180+ GMP-certified medicines in cardiology, neurology, and pain management for Ukrainian patients and export to 20+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Over-the-counter drugs
• Cardiology neurology drugs
• Pharmaceutical manufacturing

Headquarters

HQ city

Kyiv

HQ country

Ukraine

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Darnitsa generates revenue through the sale of over 180 medicinal products across cardiology, neurology, and pain management categories. Products are sold domestically through own pharmacy network, government healthcare programs, and export markets in 20+ countries.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Darnitsa is a Ukrainian pharmaceutical manufacturer that develops, produces, and markets a portfolio of 180+ medicinal products, with primary therapeutic focus on cardiology, neurology, and pain management. The company operates GMP-certified manufacturing facilities in Kyiv and exports its products to more than 20 countries, serving as a market leader in Ukraine by sales volume.

Product overview

Darnitsa is a Ukrainian pharmaceutical company and market leader by sales volume, producing over 180 medicinal products. The company operates a single unified product portfolio organized around three therapeutic focus areas: cardiology (cardiovascular disease management), neurology (including PTSD and psychological trauma treatments), and pain management (analgesics and anti-inflammatory medications). The product lineup includes both core brand medications (Ibuprofen-Darnitsa, Paracetamol-Darnitsa, Citramon-Darnitsa) and specialized formulations such as orodispersible tablets (Eridez), extended-release tablets (Darfen Long), hepatoprotective agents (Darsil), and treatments for alcohol intoxication (Medikhronal-Darnitsa). The company maintains GMP (Good Manufacturing Practice) certification and exports to more than 20 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Ibuprofen-Darnitsa

Quantifiable outcome

• Leader in Ukrainian pharmaceutical market by sales volume in natural terms
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Ukrainian Ministry of Health / Government programscoreStrategic or Co-development PartnerDarnitsa is a partner in the Ukrainian government's 'Доступні ліки' (Affordable Medicines) program, which provides subsidized medications to eligible Ukrainian patients. This partnership ensures wider accessibility of Darnitsa's pharmaceutical products to the population.
• Institute of Heart (Інститут серця)coreStrategic or Co-development PartnerJoint collaboration on the 'Серце б'ється' (Heart Beats) podcast focused on cardiovascular health education. The partnership combines Darnitsa's pharmaceutical expertise with the Institute's medical knowledge to educate the public on heart health topics.
• Army+ platformminorGTM or Marketing PartnerDarnitsa provides 20% discounts on medications to military personnel through the Army+ platform, supporting Ukrainian armed forces with affordable access to essential medicines.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Acino Ukraine (formerly Normon/Sandoz): Acino Ukraine develops, manufactures and markets branded generics in Ukraine and CIS countries with strong positions in cardiology and neurology. Its product portfolio, regulatory footprint, and sales channels closely parallel Darnitsa's, making it a direct peer for procurement and formulary share.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with a strong CEE/CIS footprint and significant cardiology and CNS portfolios. It is a comparable branded-generic manufacturer competing against Darnitsa in Ukraine and the broader Eastern European pharmacy channel.
• Polpharma: Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe, producing generic and OTC medicines with notable cardiology and neurology exposure. It shares Darnitsa's branded-generic business model and competes in overlapping CEE distribution channels.
• Farmak: Farmak is Ukraine's largest pharmaceutical manufacturer by revenue, producing a broad generic and branded portfolio across therapeutic categories including cardiology and neurology. It is Darnitsa's most direct domestic competitor, competing for the same government formulary slots, hospital tenders, and export channels.
• KRKA: KRKA is a Slovenia-based generic and branded pharmaceutical manufacturer with extensive presence across Central and Eastern Europe, including Ukraine. It competes with Darnitsa on the same generic molecules in cardiology, neurology, and pain management, and uses its EU GMP standing to win tenders across the region.
• Arterium: Arterium is a leading Ukrainian pharmaceutical group formed from Galichpharm and Kievmedpreparat, producing generic and branded medicines across cardiology, neurology and pain indications. It competes head-to-head with Darnitsa for Ukrainian market share, government procurement contracts, and CIS export volumes.
• STADA Arzneimittel: STADA is a Germany-headquartered generics and specialty pharma company with a strong CEE/CIS distribution and manufacturing footprint. Its portfolio breadth and tender-driven go-to-market are highly comparable to Darnitsa's, particularly in cardiology and pain management.
• Zentiva: Zentiva is a major European generic and branded generic manufacturer operating across CEE, including Ukraine. Its broad cardiovascular and pain management portfolio, government tender participation, and EU GMP standing make it a close functional peer to Darnitsa.

Broad incumbents

• Sanofi Ukraine: Sanofi is a global innovator and consumer-healthcare pharmaceutical company with an established Ukrainian commercial presence. While not a direct generics competitor, it competes for physician attention, hospital tenders, and cardiovascular/neurology prescriptions alongside Darnitsa's branded generic portfolio.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer, with significant operations across CEE and CIS including Ukraine. It competes broadly with Darnitsa's generics portfolio and serves as a benchmark for export scale and regulatory capacity, though its portfolio is far wider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLKO6IA9O3NjR5HQUwtiQzgvFMcqkQs-Q3
• Xx.com/darnitsapharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Darnitsa